These findings are consistent with the results of other studies that indicated the therapeutic efficacies of the IL‐6R blockade and TNF inhibition on RA activity and its clinical condition (Maini et al., 2006; Smolen et al., 2008; Nishimoto et al., 2009; Nishimoto et al., 2007; Weinblatt et al., 2003; Atzeni et al., 2006; Potter et al., 2009; Greenberg et al., 2012; Herenius et al., 2013). Here, TNF is linked to rheumatoid arthritis.